# TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults

> **NCT00573170** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 375 (actual)

## Conditions studied

- Migraine Disorders
- Migraine, Acute

## Interventions

- **DRUG:** TREXIMET®
- **DRUG:** Butalbital-containing Combination Medications (BCM)
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT00573170
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2009-08
- **Final completion:** 2009-08
- **Target enrollment:** 375 (ACTUAL)
- **Last updated:** 2010-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00573170

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00573170, "TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT00573170. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*